摘要:
4-(2,2-Difluoro-benzo[1,3]dioxol-5-ylmethyl)-piperazine-1 -carboxylic acid (4-chloro-pyridin-3-yl)-amide is described, which is useful as a FAAH modulator. 4-(2,2-Difluoro-benzo[1,3]dioxol-5-ylmethyl)-piperazine-1 -carboxylic acid (4-chloro-pyridin-3-yl)-amide may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (FAAH) activity, such as anxiety, pain, inflammation, sleep disorders, eating disorders, energy metabolism disorders, and movement disorders (e.g., multiple sclerosis). A method of synthesizing 4- (2,2-difluoro-benzo[1,3]dioxol-5-ylmethyl)-piperazine-1 -carboxylic acid (4- chloro-pyridin-3-yl)-amide is also disclosed.
摘要:
The present invention relates to compositions and methods for treating and preventing cocaine addiction. In particular, the present invention provides mutated cocaine esterase proteins for use in treating and preventing cocaine addiction.
摘要:
Provided are certain solvates of 3-methoxy- N -[3-(2-methyl-2 H -pyrazol-3-yl)-4-(2-morpholin-4-yl-ethoxy)-phenyl]-benzamide or a pharmaceutically acceptable salt thereof. Also provided are pharmaceutical compositions comprising such solvates and methods for their use.
摘要:
This invention relates to a novel arylindenopyrimidine, A, and its therapeutic and prophylactic uses. Disorders treated and/or prevented include Parkinson's Disease. Formula (I) wherein X, R 2 , R 3 , and R 4 are as defined in the specification.
摘要:
This invention relates to a novel arylindenopyrimidine, A, and its therapeutic and prophylactic uses. Disorders treated and/or prevented include Parkinson's Disease (Formula), wherein X, R 2 , R 3 , and R 4 are as defined in the specification.
摘要:
This invention relates to a novel arylindenopyrimidinc, A, and its therapeutic and prophylactic uses. Disorders treated and/or prevented include Parkinson's Disease. (Formula), wherein X, R 2 , R 3 , and R 4 are as defined in the specification.
摘要:
Dosage forms comprising at least one opioid agonist prone to abuse and at least one opioid antagonist, effective to enhance the therapeutic potency of the opioid agonists and reduce their abuse or providing effective therapeutic relief for at least 12 hours.
摘要:
L'invention se rapporte à des dérivés de 2-cycloamino-5-(pyridin-4-yl)imidazo[2,1 - b ]{\,3,4]thiadiazole de formule générale (I) dans laquelle; R 5 représente un atome d'hydrogène ou un groupe C 1-3 alkyle, - NR 7 R 8 , ou C 1-3 alkyloxy; R6 représente un groupe phényle éventuellement substitué;A représente un groupe C 1-7 -alkylène éventuellement substitué par un ou deux groupes R a ; B représente un groupe C 1-7 -alkylène éventuellement substitué par un groupe R b ; L représente soit un atome d'azote éventuellement substitué par un groupe R c ou R d , soit un atome de carbone substitué par un groupe Rei et un groupe R d ou deux groupes R e2 ; R 7 et R 8 représentent, indépendamment l'un de l'autre, un atome d'hydrogène ou un groupe C 1-3 alkyle; Procédé de préparation et application en thérapeutique.
摘要翻译:本发明涉及通式(I)的2-环氨基-5-(吡啶-4-基)咪唑并[2,1-b] [1,3,4]噻二唑衍生物,其中:R5是氢原子或 C 1-3烷基,-NR 7 R 8或C 1-3烷氧基; R6是任选取代的苯基; A是任选被一个或两个R a基团取代的C 1-7 - 烯基; B是任选被Rb基团取代的C 1-7 - 亚烷基; L是任选被Rc或Rd基团取代的氮原子,或被Rei基团和Rd基团或两个Re2基团取代的碳原子; R 7和R 8独立地为氢原子或C 1-3烷基。 本发明还涉及其制备方法及其治疗用途。